Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe

GeNO LLC Initiates Study of Inhaled NITROSYLâ„¢ Nitric Oxide in Idiopathic Pulmonary Fibrosis (PH-IPF) and Pulmonary Arterial Hypertension (PAH) Patients

March 22, 2011 By Bio-Medicine.Org

COCOA, Fla., March 22, 2011 /PRNewswire/ — GeNO LLC (www.genollc.com), a privately
held, advanced development-stage technology company, today
announced commencement of  the PHiano Study: A Phase 2,
Dose-Escalation Trial for the Treatment of Pulmonary Hypertension
in patients with Pulmonary Arterial Hypertension (PAH) and
Pulmonary Hypertension secondary to Idiopathic Pulmonary Fibrosis
(PH-IPF) using Inhaled NITROSYL™ nitric oxide (NO).  The
first patient was successfully dosed at Creighton University
Medical Center. This trial will be conducted at multiple clinical
sites in the US, and is expected to enroll up to 75 patients.
 It is designed to investigate the safety and efficacy of
various doses of inhaled nitric oxide (NO), up to a maximum of 80
ppm, delivered for up to 150 minutes with GeNO’s
stand-alone NITROSYL™ system in subjects with WHO
Group 1 PAH and WHO Group 3 PH-IPF undergoing right heart
catheterization (RHC).

The primary objective of the PHiano study is to identify the
minimally effective dose and the maximum effective dose (dose
beyond which no further effect on pulmonary vascular resistance is
seen) of inhaled NITROSYL™ nitric oxide  as compared to
placebo.  Secondary objectives include assessing the safety
and tolerability of inhaled nitric oxide and evaluating the
pharmacokinetics of total nitrates/nitrites and methemoglobin
produced following inhalation. Additional study details can be
found on http://clinicaltrials.gov/
ClinicalTrials.gov Identifier: NCT01265888.  

GeNO’s stand-alone gas cylinder stores premixed nitric oxide as
nitrogen dioxide in either air or oxygen; however, this study will
administer nitrogen dioxide only in air. The gas is allowed to flow
through GeNO’s proprietary cartridge containing ascorbic acid,
which generates nitric oxide immediately prior to inhalation.
A

‘/>”/>

SOURCE

Related Articles Read More >

Verily Study Watch
Verily says its Study Watch could identify heart failure risk
A child using a medical device at home.
Device design takes the spotlight among 2024’s top health tech hazards
These 11 medical device inventions are the best of 2023, Time magazine says
A photo of a Best Buy Geek Squad employee helping a chronic care patient with a remote monitoring device.
Device manufacturers have an unexpected ally for at-home health care
“mdo
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest medical device business news, application and technology trends.

DeviceTalks Weekly

See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to our E-Newsletter
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2025 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe